HNRNPA2B1 Protein

HNRNPA2B1 Protein

Overview

HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, a group of RNA-binding proteins that regulate pre-mRNA processing and metabolism. The protein is encoded by the HNRNPA2B1 gene located on chromosome 7 (7p15). HNRNPA2B1 exists as two protein isoforms—HNRNPA2 and HNRNPB1—generated through alternative splicing, which are often referred to collectively. The protein is predominantly localized to the nucleus but can shuttle between nuclear and cytoplasmic compartments, particularly under stress conditions. With molecular weight approximately 37-39 kDa, HNRNPA2B1 contains two RNA recognition motifs (RRMs) at its N-terminus and a glycine-rich auxiliary domain that facilitates protein-protein interactions.

Function/Biology

HNRNPA2B1 Protein

Overview

HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, a group of RNA-binding proteins that regulate pre-mRNA processing and metabolism. The protein is encoded by the HNRNPA2B1 gene located on chromosome 7 (7p15). HNRNPA2B1 exists as two protein isoforms—HNRNPA2 and HNRNPB1—generated through alternative splicing, which are often referred to collectively. The protein is predominantly localized to the nucleus but can shuttle between nuclear and cytoplasmic compartments, particularly under stress conditions. With molecular weight approximately 37-39 kDa, HNRNPA2B1 contains two RNA recognition motifs (RRMs) at its N-terminus and a glycine-rich auxiliary domain that facilitates protein-protein interactions.

Function/Biology

HNRNPA2B1 functions as a multifunctional RNA-binding protein with roles spanning from transcription to translation. In the nucleus, it participates in pre-mRNA splicing by binding to polypyrimidine tracts and other regulatory RNA sequences, influencing which exons are included or excluded during alternative splicing. The protein regulates mRNA export through interaction with transport factors and modification of mRNA secondary structures. In the cytoplasm, HNRNPA2B1 associates with other proteins to regulate mRNA stability, localization, and translation efficiency. The protein also binds to microRNAs (miRNAs) and influences miRNA biogenesis and processing, particularly through its interaction with the DGCR8-Drosha complex involved in pri-miRNA processing. Additionally, HNRNPA2B1 has been shown to regulate stress granule formation, subcellular RNA-containing bodies that form in response to cellular stress conditions.

Role in Neurodegeneration

HNRNPA2B1 has emerged as a critical player in multiple neurodegenerative diseases, with particular prominence in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Pathogenic mutations in HNRNPA2B1, including the well-characterized D290V and the N-terminal Pro9Ala substitution, have been identified in familial ALS patients. These mutations increase the propensity of HNRNPA2B1 to aggregate and form intranuclear inclusions, a hallmark pathological feature of ALS. In Alzheimer's disease, dysregulation of HNRNPA2B1 expression and altered splicing patterns have been observed, contributing to aberrant processing of amyloid precursor protein (APP) and tau protein. The protein's role in stress granule dynamics is particularly relevant to neurodegeneration, as impaired stress granule regulation can lead to cytoplasmic accumulation of pathogenic RNA-protein complexes. Furthermore, HNRNPA2B1 dysfunction appears to exacerbate the pathology associated with nucleotide repeat expansions in diseases like myotonic dystrophy, where it participates in repeat-associated non-AUG (RAN) translation.

Molecular Mechanisms

The pathogenic mechanisms involving HNRNPA2B1 in neurodegeneration involve both loss-of-function and gain-of-function effects. ALS-associated mutations impair the protein's RNA-binding capacity while promoting aberrant protein-protein interactions and self-aggregation. Mutant HNRNPA2B1 shows increased tendency to form insoluble aggregates that sequester wild-type protein and other RNA-binding proteins, compromising normal RNA metabolism. At the molecular level, mutations disrupt the balance between nuclear and cytoplasmic localization, leading to cytoplasmic accumulation and sequestration of nuclear export machinery. The protein's interaction with cryptic RNA elements becomes dysregulated, resulting in altered alternative splicing patterns that produce toxic protein variants. Importantly, mutant HNRNPA2B1 demonstrates reduced ability to suppress stress granule formation, leading to pathological granule accumulation in neurons.

Clinical/Research Significance

Mutations in HNRNPA2B1 account for a small but significant percentage of familial ALS cases, with particular prevalence in certain populations. The discovery of HNRNPA2B1 mutations has broadened understanding of the RNA metabolism dysfunction underlying ALS pathogenesis. Research indicates that HNRNPA2B1-associated ALS typically presents with upper motor neuron predominance and slower disease progression compared to typical ALS. Therapeutic strategies targeting HNRNPA2B1 include antisense oligonucleotides to modulate expression levels, aggregation inhibitors, and approaches promoting proteolytic clearance of mutant protein.

Related Entities

• Heterogeneous nuclear ribonucleoprotein family (HNRNPA1, HNRNPD, HNRNPF)
• FUS protein (similar RNA-binding protein mutations in ALS)
• TAU protein and APP (splicing targets in neurodegeneration)
• Stress granules an